InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Discover the complete record of transactions filed by Ordentlich Peter, Directeur Scientifique. Officer active across 2 companies, notably Syndax Pharmaceuticals Inc. In total, 5 reports have been recorded. History available since 31 January 2022. The latest transaction was disclosed on 15 February 2023 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations
Peter Ordentlich is the Chief Scientific Officer at Syndax Pharmaceuticals Inc. He is responsible for leading the company's research and development initiatives, ensuring innovation and advancement in pharmaceutical technologies. Peter Ordentlich plays a key role in the scientific direction of the company, contributing to its success in the biopharmaceutical field.